The effect of clove extracts on pai
Phase 2
Completed
- Conditions
- Acute ischaemic heart disease, unspecified.Acute ischaemic heart disease, unspecified
- Registration Number
- IRCT2017012332129N1
- Lead Sponsor
- Vice Chancellor for Research and Technology of Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
age between 40-60 years old; full consciousness; ability to communicate; not a severe pain in other areas; no scarring and lesions at the injection site and no history of allergy to clove. Exclusion criteria: loss of consciousness; sensorimotor disorders; injection of other drug in the abdomen during the study, and two days before the study; prescription of narcotic and non-narcotic analgesics 2 hours before injection; allergy to clove extracts.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: Immediatly after intervention. Method of measurement: Visual Analog Scale.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie clove extract's analgesic effects on acute coronary syndrome patients receiving enoxaparin injections?
How does clove extract compare to standard analgesics in managing enoxaparin injection pain for acute coronary syndrome patients?
Are there specific biomarkers that predict patient response to clove extract analgesia in acute coronary syndrome settings?
What are the potential adverse events associated with clove extract use in acute coronary syndrome patients and how can they be managed?
What other natural compounds or combination therapies show promise in alleviating enoxaparin-related injection pain in cardiovascular disease patients?